| Male/female | 8/14 |
| Median age (range) | 36 (24-54 yr) |
| Diagnosis | |
| Chronic myelogenous leukemia | 13 (59%) |
| Acute leukemia | 4 (18%) |
| Aplastic anemia | 2 (9%) |
| Myelodysplastic syndrome | 2 (9%) |
| Other | 1 (5%) |
| Conditioning | |
| Cytosine arabinoside/cyclophosphamide/TBI | 12 (55%) |
| Cyclophosphamide/TBI | 7 (32%) |
| Busulfan/cyclosphosphamide | 1 (5%) |
| Other | 2 (9%) |
| Type of transplant | |
| Allogeneic related donor | 13 (59%) |
| Unrelated donor | 6 (27%) |
| Allogeneic related donor + adoptive immunotherapy | 3 (14%) |
| Male/female | 8/14 |
| Median age (range) | 36 (24-54 yr) |
| Diagnosis | |
| Chronic myelogenous leukemia | 13 (59%) |
| Acute leukemia | 4 (18%) |
| Aplastic anemia | 2 (9%) |
| Myelodysplastic syndrome | 2 (9%) |
| Other | 1 (5%) |
| Conditioning | |
| Cytosine arabinoside/cyclophosphamide/TBI | 12 (55%) |
| Cyclophosphamide/TBI | 7 (32%) |
| Busulfan/cyclosphosphamide | 1 (5%) |
| Other | 2 (9%) |
| Type of transplant | |
| Allogeneic related donor | 13 (59%) |
| Unrelated donor | 6 (27%) |
| Allogeneic related donor + adoptive immunotherapy | 3 (14%) |